Non-insulin Anti-diabetes Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
Diabetes is a metabolic disease, wherein the body is either unable to secret insulin (type 1 diabetes) or is unable to utilize the generated insulin (type 2 diabetes). This elevated sugar level leads to various symptoms such as increased thirst & appetite, weight loss, frequent urination, fatigue, cuts and bruises that do not heal, numbness and tingling in hands and feet. If untreated, diabetes leads to various acute and chronic life-threatening complications. Approximately 90% of all cases of diabetes worldwide are type 2 diabetes mellitus. Diabetes occurs at any age; however, it is more common in adults aged 60 and above. Diabetes affects 1 in 4 people over the age of 65. People who are overweight, older, or suffering from some other diseases such as pancreatic disorders or high blood pressure are at a higher risk of developing diabetes. As of 2016, diabetes is the seventh leading cause of death. An estimated 415 million people are suffering with diabetes globally. The figure is expected to rise to 642 million by 2040.
Based on drug class, the non-insulin anti-diabetes drugs market has been segmented into GLP-1 receptor agonists (dulaglutide, exenatide), amylin analogue (pramlintide), sulphonylureas (tolbutamide, glimepiride), biguanides (metformin), alpha-glucosidase inhibitors (acarbose), DPP-4 inhibitors (alogliptin), and SGLT-2 inhibitors (canagliflozin, dapagliflozin). The SGLT-2 inhibitors segment is expected to witness strong growth due to minimal side effects and more efficacy as monotherapy as well as combination therapy. Extensive research is being carried out on SGLT2 inhibitors to develop newer and more efficient molecules belonging to this class. Currently, Novartis’ LIK066, Ionis Pharmaceuticals’ ISIS 388626, and Jiangsu Hengrui Medicine Co.’s henagliflozin (SHR-3824) are the major pipeline SGLT-2 inhibitors under clinical studies expected to be launched during the forecast period from 2017 to 2025. In terms of dosage form, the non-insulin anti-diabetes drugs market has been segmented into oral and injectable. The injectable non-insulin anti-diabetes drugs segment is expected to experience significant growth during the forecast period due to factors such as few side effects, no impact on weight of a patient, effectiveness in combination with other anti-diabetes drugs, and strong R&D activities to develop newer products. Currently, Eli Lilly and Company’s LY 3298176, Janssen Pharmaceuticals’ JNJ 54728518, and Sanofi’s SAR 425899 are the major pipeline injectable molecules under clinical development. Major factors that contribute to the growth of the non-insulin anti-diabetes drugs market include rapid rise in prevalence of diabetes across the globe, extensive R&D activities, and rising demand for economical and long-acting drugs. However, expiration of patents of various blockbuster drugs during the forecast period is the major restraint of the market.
In terms of geography, the non-insulin anti-diabetes drugs market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the non-insulin anti-diabetes drugs market, followed by Europe, due to the higher incidence and prevalence rates, large number of ongoing clinical trials, and availability of improved treatment options and health care infrastructure. Asia Pacific is an emerging market for non-insulin anti-diabetes drugs due to increasing prevalence of type 2 diabetes, gradual development of medical infrastructure, and rising awareness. However, high cost of therapy, lack of availability of treatment options, and poor patient awareness are factors restraining the non-insulin anti-diabetes drugs market in regions such as Middle East & Africa and Latin America.
Major players operating in the non-insulin anti-diabetes drugs market include Sanofi, Abbott Laboratories, Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, and Novartis International AG.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Diabetes
DiabetesChinese Markets for Diabetes Drugs
Medical DevicesNebulizers-Medical Devices Pipeline Product Landscape, 2021